Medical Oncology Unit 3, Veneto Institute of Oncology IRCCS, Padua, Italy.
Medical Oncology Unit 1, Veneto Institute of Oncology IRCCS, Padua, Italy.
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-14. doi: 10.1200/EDBK_351354.
Human epidermal growth factor receptor 2 () is a well-known oncogenic driver in different tumors and an approved therapeutic target in breast and gastroesophageal cancer. In metastatic colorectal cancer, only 3% to 5% of patients present with alterations: somatic mutations and amplifications. was first assessed as a biomarker of resistance to anti- therapy; however, in more recent years, its role as a potential actionable target has emerged. In this article, we discuss the predictive and prognostic value of in metastatic colorectal cancer, its emerging role as an actionable therapeutic target, and its possible future developments.
人表皮生长因子受体 2 () 是不同肿瘤中一种著名的致癌驱动基因，也是乳腺癌和胃食管交界处癌的一种已批准的治疗靶点。在转移性结直肠癌中，仅有 3%至 5%的患者存在 改变：体细胞突变和扩增。 最初被评估为抗治疗耐药的生物标志物；然而，在最近几年，它作为一种潜在的可操作靶点的作用已经显现出来。本文讨论了 在转移性结直肠癌中的预测和预后价值、它作为一个有前途的治疗靶点的新兴作用，以及它可能的未来发展。
